Security Matters (SMX) Stock Rallies 12% After Technology Successfully Marks And Tracks 2.2 Tons Of Silver ($SMX)

SMX PLC (NASDAQ: SMX; SMXWW) SMX PLC (NASDAQ: SMX; SMXWW) shares are firmly in rally mode after adding 12% to their value on Monday. The continuation of the bullish trajectory results from updates showing SMX’s invisible marking and tracking technology can be an invaluable addition to facilitating a circular economy for a growing number of raw materials. The latest came on Monday when SMX announced successfully completing its proof of concept for ethical sourcing and authentication of 2.2 tons of silver in cooperation with Sunshine Minting (SMI). The program covered the marking of the silver raw material through continuous manufacturing processes to final products, including recycling loops. Elements of the process demonstrate how remarkable this SMX technology is. 

Foremost is its survival through manufacturing processes. In this instance, SMX technology proved its 100% resilience through the melting stage. But the value didn’t end there. The marker technology survived further processing of that silver again at 100% levels into blanks, including casting, extrusion, rolling, annealing, blank cutting, and recycling. No other known company has shown anything near this capability. That’s important for many reasons that we’ll identify later. But know this now- with durability perfection from silver billet to finished products that provide irrefutable proof of quality and brand authentication for credible ESG reporting, this technology may become mainstream in the precious metals sectors sooner rather than later.

That’s not an overly ambitious assessment, considering the SMX Marking System provided a non-destructive way of tracing, identifying, authenticating, and validating marked silver, confirmed through blind testing comparisons that proved 100% accuracy in samples read. Moreover, the data confirmed that all the mechanical and material properties of the silver remained intact, covering tensile microstructure, hardness, and grain size.

This announcement followed another historical company milestone published last week. That one also demonstrated that SMX invisible marking technology is not only unrivaled, it may be the most valuable contributor to supply chain authenticity, corporate accountability, and global trade transparency. Better still, it faces no competitive threats.

Compiling Milestones Ahead Of Catalysts

That’s a substantial contribution to the thesis that at roughly $0.16, SMX stock may be materially undervalued. Especially factoring in the news from last week that SMX successfully marked, invisibly, twenty-one tons of natural rubber sourced in Latin America. That’s impressive on that merit alone. But consider this: This was a tree-to-tire validation process where the invisible marking was done at the tree source and then followed through manufacturing and production processes. No other known company or technology can make a similar claim.

Nor can they make this one. The SMX marker technology was added to the cup lump harvesting by the farmers before the transfer, meaning that SMX marking survived several logistics stages before it was sent to the manufacturing center, where the forty-two tons of latex was converted to twenty-one tons of natural rubber. It gets better. After evaluating the SMX marker technology on that rubber, results demonstrated 100% success in proving raw material verification, origin authentication, and full traceability regarding supply chain data and manufacturing integrity. Only then was that end product transferred to commercial car, truck, and lorry tire manufacturing, where that rubber could be tracked from tree to final tire production.

Here’s another thing to note- while SMX didn’t provide the client’s name, it’s a safe assumption that it was Continental Rubber, noting that in 2023, SMX announced its relationship with ContiTech, one of Continental’s group sectors in Hanover, Germany, to evaluate the marking technology. Notably, similar to results from its recent update, SMX said that the teams were able to 100% identify (through blind tests) the ‘marked’ and ‘unmarked’ natural rubber in engine mounts supplied by Continental for a global automotive company without affecting the material properties and the product performance. That success could open doors to other tire and rubber manufacturers like Bridgestone (OTC: BRDCY), Goodyear (NASDAQ: GT), Michelin (OTC: MGDDY), and Pirelli (OTC: PLLIF).

SMX Delivers The Next Generation Of Barcode Technology

Why would they want it? Well, there are many reasons, and every one of them is vitally important to fostering a circular economy, supply chain integrity, corporate accountability, and material source verification. And why would they turn to SMX for help? Because SMX is the only known company able to provide them the means to prove they’re delivering on commitments made to implement green, clean, and sustainable business and manufacturing processes.

In fact, beyond being the only company able to offer this tracking technology, it does so with perfection. Results published last week are the third 100% optimal read for SMX. And not just related to rubber for tires. Other projects validated natural rubber delivered by SMX for bicycle tires, engine mounts, and internal materials. While those markets present enormous revenue-generating opportunities, they are far from the only ones in the SMX crosshairs.

SMX invisible marker technology provides the same unblemished accuracy when marking metals, plastics, oils, fabric, and other raw materials. As important, the mark can’t be removed, destroyed, or altered, instead becoming a permanent part of a product’s DNA. That’s valuable because it provides companies throughout the supply chain buying, selling, or mining products with the most efficient and reliable means of identifying where products started, where they went, and how they will be reused in their life cycle. And with blockchain inclusion, that transfer chain is enhanced, earning SMX technology the right to be referenced as “The Intelligence of Things.”

That’s fitting since SMX marking technology is best described as barcodes on steroids. Remember, barcodes are static- and they still became one of the most widely adopted tools to create marketing and management efficiencies. But here’s where being better, technologically speaking, can make a huge impact on those doing business in the 21st-century digital landscape.

The current barcode technology is primarily related to product pricing and inventory. SMX technology makes that look archaic. SMX marker technology isn’t a series of black lines; it comprises a chemical-based, hidden “barcode” system with a “reader” to identify unique codes and create a blockchain record to store, maintain, and protect data ownership. The value inherent to those abilities can be invaluable to miners, manufacturers, brands, and logistics providers, especially those who understand the importance of proving its contributions to sustainable and accountable business practices.

SMX Is Scoring Major Multi-Sector Interest

That includes food and beverage giant PepsiCo (NYSE: PEP). Last month, SMX filedabout its excitement to share a pilot program with that company to deter counterfeiting and ensure that product authenticity is complete. The success of initial tests has moved the program toward finalizing an agreement that could scale the technology across their operations, providing PEP with accurate identification of marked PepsiCo packaging to validate supply chain transparency and safeguard brand integrity. If a final agreement is reached, the terms could be a massive revenue driver for SMX, considering the product volume associated with PepsiCo and their intent to promote and track sustainability initiatives across their European supply chain. They are far from the only company interested.

SMX continues adding to a Who’s Who customer list that is interested in using its blockchain-tech system to identify, sort, monitor, and pack waste. That includes the Perth Mint, the North American Flame Retardant Alliance (NAFRA), LVMH Métiers d’Art (OTC: LVMHF), and the Israeli Cotton Board. Those established names represent just the tip of the revenue-generating iceberg regarding new client opportunities. Thousands of companies are committed to traceability, accountability, recycling, and fostering a global circular economy. Utilizing SMX can prove that they are delivering on that intent.

But know this- new client opportunities extend well beyond the private sector. SMX technology could become one of the most potent weapons in a homeland security arsenal. Keep in mind that the vast profits made without supply chain checks and balances often support global terrorism, an area of concern needing no introduction to most. While tracing these dollars through conventional manufacturing and transporting channels has been hard to stop, at least it’s now possible. Thank SMX for that.

Tracking Illicit Dollars Through The Supply Chain

Its technology is precisely the type of technological asset needed to combat supply chain fraud and deficiencies. And there’s plenty to target, evidenced by countries spending billions to prevent black market trade. The United States’s budget allocation for homeland security is expected to eclipse the $49.8 billion spent in 2021, sourcing innovative technology, like SMX’s, to counter immersive threats. That’s just the United States. Billions more are in play from other countries, many of which have an immediate need to bolster national security infrastructures. The market opportunities extend further for SMX. Companies and sectors also need protection. And some may eventually be required to fortify their operational defenses.

That could include companies in the digital assets sector like RIOT Platforms (Nasdaq: RIOT), Marathon Digital (Nasdaq: MARA), and CleanSpark (Nasdaq: CLSK). Due to their sector-user’s anonymity and ease of transfer, digital assets can significantly threaten global homelands. No one’s inferring they allow that to happen. Those are respected companies, but considering the millions in daily transactions, they could unintentionally provide a pathway to funding less-than-desirable occurrences. Those few highlight a significant consideration: Every company, food, beverage, digital asset, or material must, in any way it can, ally on the side of homeland protection. SMX may be the go-to option. 

And with the news on Monday, SMX may be able to exploit a sweet spot of opportunity within the precious metals sector, with SMX likely piquing the interest of companies like First Majestic Silver (NYSE: AG), BHP Group (NYSE: BHP), Silvercorp Metals (NYSE: SVM), and others. Remember, like digital assets, metals are also used in trade with relative anonymity. Thus, with a means available to trace provenance from mine to bar, product, or coin, widespread sector adoption is undoubtedly an opportunity in play.

A Value Proposition Exposed

That adds to an SMX value proposition worth seizing. In fact, the current SMX stock price may be as ground floor as it gets at sub-dollar prices. That’s a logical assumption, considering this company’s game-changing technology may forever change, for the better, supply chain life cycles, circular economy initiatives, corporate accountability, transparency, and product authenticity.

Thus, don’t be surprised to hear much more about SMX in 2024 or that the stock’s path of least resistance continues to get paved higher. It’s earned that privilege. Remember, its invisible marker technology is more than a potent tool to fight global supply chain destruction; it can be essential to homeland security defenses in the digital age, transforming the milestone deals made in 2023 and 2024 into growth catalysts.

The bottom line is simple: For growth stock investors who like to seize on valuation disconnects, there may be no better opportunity than this one.

 

Disclaimers: Hawk Point Media Group, Llc. is responsible for the production and distribution of this content.  Hawk Point Media Group, Llc. is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by  Hawk Point Media Group, Llc. is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall  Hawk Point Media Group, Llc. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by  Hawk Point Media Group, Llc., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations.  Hawk Point Media Group, Llc. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content,  Hawk Point Media Group, Llc., its authors, contributors, or its agents, may be compensated  for preparing research, video graphics, and editorial content. HPM, LLC has been compensated three-thousand-five-hundred-dollars via bank wire by a third unrelated party to provide this research and/or editorial production coverage for SMX PLC. for a period starting on 04/05/24 and ending on 03/09/24. HPM LLC. was previously compensated two-thousand-five-hundred-dollars to provide similar services for a one month period starting on 4/30/24 and ending on 10/20/23. HPM LLC. was previously paid four-thousand-five-hundred-dollars via bank transfer by Trending Equities LLC for digital production and syndication services beginning on March 1, 2023 and ending on March 31, 2023. Thus, readers of this content should note that SMX PLC is portrayed favorably. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that are attached to this content. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. 

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Security Matters (SMX) Stock Rallies 12% After Technology Successfully Marks And Tracks 2.2 Tons Of Silver ($SMX)

Unleashing AI in Healthcare: The Game-Changing Partnership Between Treatment AI (CSE: TRUE) and aiXplain concurrent with Federal Momentum

“Health Care AI Stocks”
Healthcare AI related stocks to keep an eye on include Exscientia PLC (NASDAQ: EXAI), Certara Inc. (NASDAQ: CERT), Relay Therapeutics Inc. (NASDAQ: RLAY), BioXcel Therapeutics Inc. (NASDAQ: BTAI), Royalty Pharma PLC (NASDAQ: RPRX), Alphabet Inc. (NASDAQ: GOOGL), Amazon.com Inc. (NASDAQ: AMZN), International Business Machines Corp. (NYSE: IBM), Healwell Al Inc (TSE: AIDX), GE HealthCare Technologies Inc.’s (NASDAQ:GEHC) and VERSES AI Inc (OTCMKTS: VRSSF) (CBOE:VERS)

In a significant development for the healthcare technology sector, Treatment.com AI Inc. has not only announced a strategic partnership with aiXplain, Inc., but also welcomed a robust federal investment in AI, heralded by Prime Minister Justin Trudeau. These two pivotal moments are set to synergize, propelling the reach and efficacy of advanced healthcare diagnostics and treatments through AI.

Federal Support for AI

On April 7, 2024, Prime Minister Trudeau announced that the Canadian government plans to allocate $2.4 billion in its upcoming budget to bolster AI adoption, with $200 million earmarked specifically for sectors including healthcare. This substantial funding initiative is designed to facilitate the adoption of AI technologies that promise to deliver positive impacts across various sectors. For Treatment.com AI, this financial backing is a timely boon that enhances its mission to disrupt healthcare using AI.

Details of the aiXplain Partnership

Concurrent with federal momentum, Treatment.com AI is set to integrate its Global Library of Medicine (GLM) into aiXplain’s dynamic AI marketplace. This partnership will enable healthcare organizations worldwide to access a state-of-the-art AI engine that boasts more than 92% accuracy on first diagnoses and offers comprehensive medical insights. The collaboration aims to democratize sophisticated AI tools, making them accessible to a wider healthcare audience globally.

Strategic Impact and Future Prospects

This dual thrust of federal support and strategic partnership fuels Treatment’s potential to transform healthcare diagnostics. The company plans to expand the GLM’s capabilities across multiple languages and platforms internationally. Additionally, Treatment and aiXplain will explore developing new AI-driven solutions that could revolutionize global healthcare markets.

Dr. Essam Hamza, CEO of Treatment.com AI, sees these developments as pivotal. “The combined support of the federal government and our new partnership with aiXplain will enable us to push the boundaries of what AI can achieve in healthcare,” he noted. The federal funding and the collaboration are expected to foster innovation and streamline the implementation of AI solutions in healthcare, potentially improving patient outcomes and operational efficiency across the sector.

The Impact of GLM and AI on Healthcare

The GLM, Treatment’s flagship AI technology, has proven its worth by passing a medical clinical exam with a success rate exceeding 92%. It is designed to alleviate burdens on healthcare professionals by automating routine tasks such as patient history intake and chart notes, allowing them to focus on critical patient care. This is increasingly vital as healthcare systems worldwide face challenges like professional burnout and staff shortages.

The strategic alliance between Treatment.com AI and aiXplain, coupled with substantial federal investment, marks a transformative chapter in healthcare technology. By facilitating wider access to the GLM through aiXplain’s platform, and leveraging governmental support, this partnership is poised to redefine healthcare standards globally. For investors and traders, this represents a compelling opportunity. As Treatment.com AI leverages these developments to enhance its market position, its stock is likely to become even more attractive to those looking to invest in the future of healthcare technology.

Stay tuned, as this evolving story promises to innovate and improve health outcomes worldwide, heralding a new era of AI in healthcare. Other Healthcare AI related stocks to keep an eye on include Exscientia PLC (NASDAQ: EXAI), Certara Inc. (NASDAQ: CERT), Relay Therapeutics Inc. (NASDAQ: RLAY), BioXcel Therapeutics Inc. (NASDAQ: BTAI), Royalty Pharma PLC (NASDAQ: RPRX), Alphabet Inc. (NASDAQ: GOOGL), Amazon.com Inc. (NASDAQ: AMZN), International Business Machines Corp. (NYSE: IBM), Healwell Al Inc (TSE: AIDX), GE HealthCare Technologies Inc.’s (NASDAQ:GEHC) and VERSES AI Inc (OTCMKTS: VRSSF) (CBOE:VERS)

 

Disclaimer: This news article is for information purposes only and is neither a solicitation or recommendation to buy nor an offer to sell securities. The Bull Report is not-a-registered-investment-advisor. The Bull Report is not a broker-dealer. Information, opinions, and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. The Bull Report accepts no liability for any losses arising from an investor’s reliance on the use of this material. Starting on Mar 15, 2024 The Bull Report has been compensated $47,000 per month for coverage of TRUE by Sunburst Capital Corp. The Bull Report and its affiliates or officers may purchase, hold, and sell shares of common stock of this stock, in the open market at any time without notice. The Bull Report will not update its purchases and sales of this stock in any future postings on The Bull Report’s websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words “may”, “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” ” project,” and similar expressions and variations thereof are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *The Bull Report does not set price targets on securities. Never invest in a stock discussed on this website or in this email alert unless you can afford to lose your entire investment.

Sources: 

https://finance.yahoo.com/news/treatment-com-ai-welcomes-federal-120000957.html

https://www.cbc.ca/news/politics/federal-government-ai-investment-1.7166234

https://finance.yahoo.com/news/treatment-com-ai-funded-national-120000374.html

https://ca.finance.yahoo.com/news/healwell-ai-pentavere-achieves-validation-110000955.html

https://finance.yahoo.com/quote/TRUE.CN/

Media Contact
Company Name: TheBullReport
Contact Person: Jason Roy
Email: info@thebullreport.com
City: Dallas
State: Texas
Country: United States
Website: https://www.thebullreport.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Unleashing AI in Healthcare: The Game-Changing Partnership Between Treatment AI (CSE: TRUE) and aiXplain concurrent with Federal Momentum

General Silicones to Showcase Innovative Silicone Solutions at Hannover Messe 2024

A Variety of Industrial Silicone Products and Silicone Decorative Film

Hsinchu, Taiwan – April 16, 2024 – General Silicones Co., Ltd. (GS), renowned for its expertise in silicone technology, is thrilled to participate in Hannover Messe 2024, showcasing a spectrum of innovative silicone products. From April 22-26, visitors can explore GS’s cutting-edge solutions at Hall 3, Stand A64-12, including their hallmark Compo-SiL® silicone decorative film.

With a legacy spanning over 50 years, GS is dedicated to delivering bespoke silicone solutions as evidenced by its one-stop shop and OEM/ODM services. This approach encompasses everything from material formulation to final product quality assurance, ensuring unparalleled service and product excellence.

Industrial Silicone Products

Attendees will discover GS’s extensive range of industrial silicone products, including silicone hybrid components, bellows, keypads and sealing gaskets, each designed for robust performance and durability. The spotlight will also be on the innovative Compo-SiL® decorative film, a silicone-based material perfect for enhancing aesthetics and functionality in various applications.

GS invites industry professionals to experience the versatility and excellence of their silicone solutions firsthand. Explore the realm of industrial silicone applications and learn about the advanced silicone molding techniques that set GS apart in the field of silicone manufacturing.

Customized Silicone Surface Treatments

GS highlights its specialization in customized surface treatments, offering a variety of finishes such as spraying, printing, laser etching, and advanced coatings encompassing silicone, silky, PU, parylene, epoxy, and chrome plating. These bespoke services underscore GS’s commitment to delivering tailored solutions, including tool design and machining, liquid injection molding, solid extrusion molding, thermal compression molding, calendaring, and extrusion to meet the diverse needs of industries.

Compo-SiL® Silicone-Based Decorative Film

General Silicones is proud to feature its owned brand, Compo-SiL®, at the forefront of its presentation. Compo-SiL® is a groundbreaking silicone-based decorative film, ideal for IMD/OMD processes, demonstrating exceptional bonding properties and versatility in design. Attendees will witness the unique advantages of Compo-SiL®, including its eco-friendly composition, halogen-free nature, and low VOC emissions, making it a prime choice for automotive, medical, and industrial applications.

For more information on General Silicones and their product offerings, please visit General Silicones and explore their Compo-SiL® decorative film.

For more information on industrial silicone products and Compo-SiL® or to book an appointment at Hannover Messe 2024, contact the sales team for the silicone solutions team or Compo-SiL® at compo-sil@gsweb.com.tw

About General Silicones

General Silicones (GS) was founded in 1970 in Taiwan and is now represented worldwide – including in Europe, China, Japan, and South-East Asian countries. GS is a major distributor of silicone materials and an active silicone products manufacturer with ISO 9001, IATF 16949, and ISO 14001 certifications. The company has manufacturing plants in Hsinchu, Taiwan; Wujiang, China; and Bac Giang, Vietnam. With decades of experience, GS provides a wide range of silicone products for many industries, including medical, automobile, consumer products, electronics, and IT.

For more information about GS, please visit www.generalsilicones.com

For more information on Compo-SiL®, please visit www.compo-sil.com

Media Contact
Company Name: GlobalPR Agency
Contact Person: Kayla Lee
Email: Send Email
Phone: +886-2-2882-5577
City: Taipei City
Country: Taiwan
Website: https://www.globalpr.agency/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: General Silicones to Showcase Innovative Silicone Solutions at Hannover Messe 2024

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

Company is targeting pancreatic cancer pain with advanced nerve detection and treatment technology

New York – March 15, 2024 – Benzinga has published a new article on Autonomix Medical Inc. (NASDAQ: AMIX), featuring the company’s groundbreaking approach to peripheral nervous system (PNS) disorders. The Benzinga article delves into the critical role of the PNS in human health and highlights how Autonomix Medical is pioneering with its catheter-based microchip sensing array technology.

The article provides a comprehensive look at how Autonomix Medical is redefining treatment protocols for nerve-related disorders. By targeting the root causes associated with the PNS, rather than just managing symptoms, Autonomix Medical’s technology offers a novel solution that combines both detection and ablation of problematic nerves in a single procedure. This approach, likened to a “GPS” for nerve treatment, allows for precise identification and treatment of the nerves involved, enhancing the accuracy and effectiveness of procedures.

In a notable application, the company is focusing its efforts on managing pancreatic cancer pain—a condition notoriously difficult to treat due to its proximity to critical nerves. The technology’s high sensitivity in detecting neural signals—up to 3,000 times greater than existing technologies—promises not only to improve outcomes in pain management but also to significantly reduce the need for opioids, addressing a major public health challenge.

This exposure in Benzinga underscores the potential of Autonomix Medical’s technology to transform the field of electrophysiology and pain management, potentially tapping into a market exceeding $100 billion. As the company progresses with its clinical trials, the successful implementation of its technology could revolutionize treatment approaches for a wide range of diseases, offering hope to millions of patients worldwide.

To read the full article, click here.

More Pancreatic Cancer News:

  • Candel Therapeutics, Inc. ((Nasdaq: CADL) announced that the FDA has granted Orphan Drug Designation to their advanced biological immunotherapy, CAN-2409, for treating pancreatic cancer, following promising phase 2 clinical trial results that more than doubled median overall survival when added to standard care.
  • RenovoRx, Inc. (Nasdaq: RNXT) announced an $11.1 million private placement, extending their financial runway into 2026, which will support the continuation and completion of their pivotal Phase III TIGeR-PaC clinical trial for pancreatic cancer. This funding also facilitates the expansion of their Trans-Arterial Micro-Perfusion (TAMP) clinical development pipeline into additional cancer indications.

Note: The details provided in this press release are based on information featured in the Benzinga article and do not constitute forward-looking statements.

Media Contact
Company Name: Plato Data Intelligence
Contact Person: Bryan Feinberg
Email: Send Email
Phone: +1551 574-2169
Address:144 E 44th Street
City: New York
State: New York
Country: United States
Website: platodata.io

Chi Dog: Unleashing the Power of Holistic Healing Through Food Therapy

In a world where pet owners are increasingly conscious of their furry friends’ health and well-being, Chi Dog emerges as a beacon of hope, offering integrative food therapy for dogs. Chi Dog’s mission is simple yet profound: to provide dogs with nutritionally balanced, therapeutic meals that harness the power of holistic healing. More information can be found at https://chidog.com

The Chi Dog Approach

At Chi Dog, every aspect of the dog’s diet is carefully curated to promote optimal health and vitality. Here’s what sets Chi Dog apart:

Real Ingredients, Real Nutrition

Chi Dog prides itself on using only 100% real ingredients sourced from trusted suppliers. From human-grade meats to wholesome veggies, every component of Chi Dog meals is selected for its nutritional value and healing properties.

Vet-Designed Formulas

Led by holistic veterinarians with over 32 years of experience, Chi Dog’s formulations are meticulously crafted to meet and exceed the nutritional needs of dogs. These formulations are developed in accordance with AAFCO standards, ensuring that dogs receive a balanced diet tailored to their specific requirements.

Guided by Eastern Medicine

Chi Dog’s approach is deeply rooted in Eastern medicine principles, particularly Traditional Chinese Food Therapy. By incorporating these ancient wisdoms into modern-day pet nutrition, Chi Dog aims to restore balance and harmony within dogs’ bodies, addressing not just symptoms but underlying imbalances.

Made Fresh in USDA Kitchens

Safety and quality are paramount at Chi Dog. All meals are cooked fresh in USDA-inspected kitchens, adhering to the highest standards of cleanliness and hygiene. Laboratory testing further ensures that every meal is free from harmful contaminants, giving pet owners peace of mind with every serving.

The Chi Dog Experience

Personalized Meal Plans

Chi Dog recognizes that every dog is unique. That’s why they offer personalized meal plans tailored to each dog’s individual needs. Through a simple three-step process, pet owners can introduce their furry companions to Chi Dog’s wholesome meals:

  1. Introduce Us To Your Fur Baby: Share some basic information about your dog to help Chi Dog understand their dietary requirements.
  2. The Perfect Formulation: Complete a short quiz designed by Chi Dog’s veterinarians to determine the ideal formulation for your dog’s health and well-being.
  3. Delivered To Your Door: Once the perfect formulation is identified, Chi Dog takes care of the rest. Meals are cooked fresh and delivered straight to the dog’s doorstep, ready to nourish and delight.

Healing Whole Foods

Chi Dog believes in the power of whole foods to promote healing and vitality. Each ingredient is selected with care, ensuring that every meal is packed with nutrients essential for optimal health. From low-carbohydrate recipes to USDA kitchen standards, Chi Dog’s commitment to quality shines through in every bite.

Our Story

Holistic Roots

Chi Dog’s journey began with Dr. Bohrer, an integrative veterinarian certified in Traditional Chinese Food Therapy. Witnessing the transformative effects of home-cooked diets on her patients, Dr. Bohrer was inspired to share this healing approach with pet owners nationwide. Thus, Chi Dog was born, driven by a passion for holistic health and a commitment to canine well-being.

Frequently Asked Questions

Empowering Pet Owners

Chi Dog understands that pet owners may have questions about their dog’s diet and nutrition. That’s why they provide a comprehensive FAQ section, addressing common queries such as:

  • Why is an Eastern Medicine Diet better than a regular diet I can find in the store?Eastern Medicine Diets, such as those offered by Chi Dog, take a holistic approach to pet nutrition, considering not just the nutritional content but also the energetics of food. This approach aims to restore balance and harmony within the body, leading to overall better health and well-being for your dog.
  • Does Chi Dog meet AAFCO standards?Yes, all formulations by Chi Dog are developed in accordance with AAFCO (Association of American Feed Control Officials) standards, ensuring that they provide complete and balanced nutrition for dogs of all life stages.
  • What do you mean by “Whole Foods”?”Whole Foods” refers to foods that are minimally processed and contain little to no artificial additives or preservatives. At Chi Dog, we use real, whole ingredients sourced from trusted suppliers, ensuring that your dog receives nutrition in its most natural form.
  • How does a fresh, lightly cooked food (like Chi Dog) compare to a raw diet?While both fresh, lightly cooked foods and raw diets offer benefits, such as increased digestibility and nutrient absorption, Chi Dog’s approach provides an additional layer of safety by lightly cooking meals to reduce the risk of bacterial contamination while still preserving essential nutrients.
  • Does Chi Dog have any preservatives?No, Chi Dog meals are free from artificial preservatives. We believe in providing dogs with the freshest, most natural ingredients possible to support their health and well-being.
  • Why are carbohydrates included in the Chi Dog diets?Carbohydrates play a role in providing energy and supporting digestive health in dogs. However, Chi Dog focuses on using low-glycemic carbohydrates and incorporates them in moderation to ensure a balanced diet that aligns with holistic health principles.
  • My dog is allergic to some ingredients in the food that is designed for their Element, should I try it?If your dog has known allergies or sensitivities, we recommend consulting with a veterinarian before introducing any new diet. Chi Dog offers personalized meal plans and formulations, allowing us to tailor meals to your dog’s specific dietary needs.
  • How is Chi Dog shipped?Chi Dog meals are carefully packaged and shipped with consideration for freshness and safety. We use insulated packaging and expedited shipping methods to ensure that meals arrive fresh and ready to serve at your doorstep.

Explore Chi Dog

Discover the Menu

Chi Dog offers a range of formulations to suit every dog’s needs, including Earth Diet, Fire Diet, Metal Diet, Water Diet, Wood Diet, and DIY Supplements. With Chi Dog, pet owners can rest assured that their furry companions are receiving the highest quality nutrition tailored to their unique requirements.

Contact Chi Dog

For inquiries, support, or to get started on your dog’s journey to optimal health, reach out to Chi Dog:

  • Address: 310 N. Indian Hill Blvd #624, Claremont, CA 91711
  • Phone (Text): 856-431-5502
  • Email: support@chidog.com

Connect with Chi Dog on social media and explore their video series and blog for valuable insights into pet nutrition and holistic health.

Chi Dog: Where Food Is Medicine and Every Ingredient Counts.

Media Contact
Company Name: Chidog
Email: Send Email
Country: United States
Website: https://chidog.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chi Dog: Unleashing the Power of Holistic Healing Through Food Therapy

Acute Pain Market Size in the 7MM is Expected to Grow by 2032 | DelveInsight

DelveInsight’s “Acute Pain Market Insights, Epidemiology, and Market Forecast — 2032” report delivers an in-depth understanding of the Acute Pain, historical and forecasted epidemiology as well as the Acute Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.

 

Key Takeaways from the Acute Pain Market Research Report

  • The increase in Acute Pain Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
  • As per DelveInsight analysis, the Acute Pain market is anticipated to witness growth at a considerable CAGR.
  • The leading Acute Pain Companies working in the market include Johnson & Johnson, Eli Lilly, Pfizer, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Baxter International Inc., Purdue Pharma, Endo Pharmaceuticals Plc., Forest Laboratories Inc., and others.
  • Promising Acute Pain Pipeline Therapies in the various stages of development include  Diclofenac Sodium Patch, Methoxyflurane, Diclofenac 50, Tramadol 50, IV Acetaminophen, VX-548, HB/APAP, and others.
  • March 2024: Vertex Pharmaceuticals Incorporated announced a study of Phase 3 clinical trials for VX-548 and HB/APAP. The purpose of this study is to evaluate the efficacy and safety of VX-548 for acute pain after a bunionectomy.
  • March 2024: Mylan Specialty LP announced a study of Phase 3 clinical trials for MR-107A-02 and Tramadol. MR-107A-02 is being studied to investigate its efficacy and safety for treatment of acute pain after herniorrhaphy.
  • January 2024: Endo Pharmaceuticals announced a study of Phase 3 clinical trials for Oxymorphone immediate release. The purpose of this study is to evaluate the analgesic efficacy and safety of two doses of oxymorphone immediate release (IR) compared to placebo and oxycodone in post-surgical pain.

 

Discover which therapies are expected to grab the Acute Pain Market Share @ Acute Pain Market Outlook

 

Acute Pain Overview

Acute pain refers to a type of pain that typically arises suddenly, has a specific cause, and is relatively short-lived. It serves as a protective mechanism signaling an injury, illness, or tissue damage, often prompting individuals to take action to address the underlying problem. Acute pain usually resolves as the underlying condition heals.

 

Acute Pain Epidemiology Insights

The epidemiology section of Acute Pain offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

  • Total Acute Pain Incidence Cases
  • Total Acute Pain Diagnosed Incident Cases
  • Acute Pain Type-specific Diagnosed Incident Cases
  • Acute Pain Severity-specific Diagnosed Incident Cases
  • Total Acute Pain Treated Cases

 

Download the report to understand which factors are driving Acute Pain Epidemiology trends @ Acute Pain Epidemiological Insights

 

Acute Pain Drugs Market

The Acute Pain Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Acute Pain signaling in Acute Pain are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Acute Pain Treatment Market Landscape

The Acute Pain treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Acute Pain has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To know more about Acute Pain treatment guidelines, visit @ Acute Pain Treatment Market Landscape

 

Acute Pain Market Outlook

The report’s outlook on the Acute Pain market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Acute Pain therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Acute Pain drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Acute Pain market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Acute Pain Drugs Uptake

The drug chapter of the Acute Pain report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, disadvantages of each drug, as well as the latest news and press releases related to Acute Pain.

 

Major Acute Pain Companies

Several Acute Pain Companies working in the market include Johnson & Johnson, Eli Lilly, Pfizer, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Baxter International Inc., Purdue Pharma, Endo Pharmaceuticals Plc., Forest Laboratories Inc., and others.

 

Learn more about the FDA-approved drugs for Acute Pain @ Drugs for Acute Pain Treatment

 

Scope of the Acute Pain Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Acute Pain Companies- Johnson & Johnson, Eli Lilly, Pfizer, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Baxter International Inc., Purdue Pharma, Endo Pharmaceuticals Plc., Forest Laboratories Inc., and others.
  • Acute Pain Pipeline Therapies- Diclofenac Sodium Patch, Methoxyflurane, Diclofenac 50, Tramadol 50, IV Acetaminophen, VX-548, HB/APAP, and others.
  • Acute Pain Market Dynamics: Acute Pain Market Drivers and Barriers
  • Acute Pain Market Access and Reimbursement, Unmet Needs, KOL’s Views, and Analyst’s Views

 

Discover more about Acute Pain Drugs in development @ Acute Pain Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Report Introduction

3. Acute Pain Market Overview at a Glance

4. Executive Summary of Acute Pain

5. Acute Pain Epidemiology and Market Methodology

6. Disease Background and Overview: Acute Pain

7. Acute Pain Patient Journey

8. Acute Pain Epidemiology and Patient Population

9. Key Endpoints in Acute Pain Clinical Trials

10. Acute Pain Marketed Drugs

11. Emerging Acute Pain Drugs

12. Conjoint Analysis

13. Acute Pain Market Analysis

14. Acute Pain KOL Views

15. Acute Pain Unmet needs

16. SWOT Analysis

17. Acute Pain Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Pain Market Size in the 7MM is Expected to Grow by 2032 | DelveInsight

Acute Lymphocytic Leukemia Market Size in the 7MM was ~USD 1100 Million in 2021 | DelveInsight

DelveInsight’s “Acute Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast — 2032” report delivers an in-depth understanding of the Acute Lymphocytic Leukemia, historical and forecasted epidemiology as well as the Acute Lymphocytic Leukemia market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.

 

Key Takeaways from the Acute Lymphocytic Leukemia Market Research Report

  • The increase in Acute Lymphocytic Leukemia Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
  • As per DelveInsight analysis, the Acute Lymphocytic Leukemia market is anticipated to witness growth at a considerable CAGR.
  • The leading Acute Lymphocytic Leukemia Companies working in the market include Novartis AG, Gracell Biotechnologies Inc, Pfizer Inc, Bristol-Myers Squibb Co, Hebei Senlang Biotechnology Co Ltd, PersonGen BioTherapeutics (Suzhou) Co Ltd., and others.
  • Promising Acute Lymphocytic Leukemia Pipeline Therapies in the various stages of development include Inotuzumab Ozogamicin, clofarabine, cytarabine and mitoxantrone, Blinatumomab, and others.

 

Discover which therapies are expected to grab the Acute Lymphocytic Leukemia Market Share @ Acute Lymphocytic Leukemia Market Outlook

 

Acute Lymphocytic Leukemia Overview

Acute lymphocytic leukemia (ALL), also known as acute lymphoblastic leukemia, is a type of cancer that affects the blood and bone marrow. It starts from young white blood cells called lymphocytes in the bone marrow; mainly characterized by an overproduction of immature white blood cells, called lymphoblasts or leukemic blasts. Because the bone marrow is unable to make adequate numbers of red cells, normal white cells, and platelets, people with ALL become more susceptible to anemia, recurrent infections, and bruising and bleeding easily. The blast cells can then spill out of the bone marrow into the bloodstream and accumulate in various organs including the lymph nodes or glands, spleen, liver, and central nervous system (brain and spinal cord).

 

Acute Lymphocytic Leukemia Epidemiology Insights

The epidemiology section of Acute Lymphocytic Leukemia offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

  • Total Acute Lymphocytic Leukemia incident cases
  • Acute Lymphocytic Leukemia gender-specific cases
  • Acute Lymphocytic Leukemia age-specific cases
  • Acute Lymphocytic Leukemia subtype-specific cases
  • Acute Lymphocytic Leukemia genetic-mutation specific cases
  • Total Acute Lymphocytic Leukemia treated cases

 

Download the report to understand which factors are driving Acute Lymphocytic Leukemia Epidemiology trends @ Acute Lymphocytic Leukemia Epidemiological Insights

 

Acute Lymphocytic Leukemia Marketed Drugs

  • TECARTUS (brexucabtagene autoleucel): Gilead Sciences
  • KYMRIAH (tisagenlecleucel): Novartis
  • RYLAZE (asparaginase Erwinia chrysanthemi recombinant/JZP458): Jazz Pharmaceuticals

 

Acute Lymphocytic Leukemia Emerging Drugs Profile

  • Orca-T: Orca Biosystems
  • Daratumumab: Janssen Research & Development
  • Obecabtagene autoleucel (obe-cel): Autolus Therapeutics

 

Acute Lymphocytic Leukemia Drugs Market

The Acute Lymphocytic Leukemia Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Acute Lymphocytic Leukemia signaling in Acute Lymphocytic Leukemia are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Acute Lymphocytic Leukemia Treatment Market Landscape

The Acute Lymphocytic Leukemia treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Acute Lymphocytic Leukemia has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To know more about Acute Lymphocytic Leukemia treatment guidelines, visit @ Acute Lymphocytic Leukemia Treatment Market Landscape

 

Acute Lymphocytic Leukemia Market Outlook

The report’s outlook on the Acute Lymphocytic Leukemia market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Acute Lymphocytic Leukemia therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Acute Lymphocytic Leukemia drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Acute Lymphocytic Leukemia market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Acute Lymphocytic Leukemia Drugs Uptake

The drug chapter of the Acute Lymphocytic Leukemia report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Acute Lymphocytic Leukemia.

 

Major Acute Lymphocytic Leukemia Companies

Several Acute Lymphocytic Leukemia Companies working in the market include Novartis AG, Gracell Biotechnologies Inc, Pfizer Inc, Bristol-Myers Squibb Co, Hebei Senlang Biotechnology Co Ltd, PersonGen BioTherapeutics (Suzhou) Co Ltd., and others.

 

Learn more about the FDA-approved drugs for Acute Lymphocytic Leukemia @ Drugs for Acute Lymphocytic Leukemia Treatment

 

Scope of the Acute Lymphocytic Leukemia Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Acute Lymphocytic Leukemia Companies- Novartis AG, Gracell Biotechnologies Inc, Pfizer Inc, Bristol-Myers Squibb Co, Hebei Senlang Biotechnology Co Ltd, PersonGen BioTherapeutics (Suzhou) Co Ltd., and others.
  • Acute Lymphocytic Leukemia Pipeline Therapies- Inotuzumab Ozogamicin, clofarabine, cytarabine and mitoxantrone, Blinatumomab, and others.
  • Acute Lymphocytic Leukemia Market Dynamics: Acute Lymphocytic Leukemia Market Drivers and Barriers
  • Acute Lymphocytic Leukemia Market Access and Reimbursement, Unmet Needs, KOL’s Views, and Analyst’s Views

 

Discover more about Acute Lymphocytic Leukemia Drugs in development @ Acute Lymphocytic Leukemia Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary of ALL

4. Key Events

5. Epidemiology and Market Methodology

6. Acute Lymphoblastic Leukemia Market Overview at a Glance

7. Disease Background and Overview

8. Current Treatment Practices: ALL

9. Treatment Guidelines

10. Epidemiology and Patient Population of 7MM

11. Patient Journey

12. Marketed Drugs

13. Emerging Drugs

14. ALL: 7MM Market Analysis

15. KOL Views

16. Unmet Needs

17. SWOT Analysis

18. Market Access and Reimbursement

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Lymphocytic Leukemia Market Size in the 7MM was ~USD 1100 Million in 2021 | DelveInsight

Acute Myeloid Leukemia Market Size is Expected to Grow by 2032 | DelveInsight

DelveInsight’s “Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast — 2032” report delivers an in-depth understanding of the Acute Myeloid Leukemia, historical and forecasted epidemiology as well as the Acute Myeloid Leukemia market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.

 

Key Takeaways from the Acute Myeloid Leukemia Market Research Report

  • The increase in Acute Myeloid Leukemia Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
  • As per DelveInsight analysis, the Acute Myeloid Leukemia market is anticipated to witness growth at a considerable CAGR.
  • The leading Acute Myeloid Leukemia Companies working in the market include Pfizer, Bristol Myers Squibb, Agios Pharmaceuticals, Abbvie, Jazz Pharmaceuticals, Astellas Pharma, Pfizer, Novartis Oncology, Daiichi Sankyo., Bristol Myers Squibb, AstraZeneca/Aex Pharmaceuticals, Inc., Chimerix, Takeda, Rafael Pharmaceuticals Inc., Delta-Fly Pharma, GlycoMimetics Incorporated, BerGenBio ASA, MacroGenics, Syndax Pharmaceuticals, Arog Pharmaceuticals, Forma Therapeutics, Sellas Life Sciences Group, Actinium Pharmaceuticals, Clear Creek Bio Inc., CellCentric Ltd., Biosight Ltd., Astex Pharmaceuticals, Inc., Curis, Inc., NexImmune Inc., Immunomedics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Incyte Corporation, Aprea Therapeutics, Immunicum/DCPrime BV, GT Biopharma Inc, Hanmi Pharmaceutical Company Limited, Cardiff Oncology, Bio-Path Holdings, Actinium Pharmaceuticals, Aptevo Therapeutics, Synimmune GmbH, GEMoaB Monoclonals, ImmunoGen Inc, AGC Biologics S.p.A., Precigen Inc, Novartis Pharmaceuticals, Xencor, Inc./Novartis, Celgene/Bristol Myers Squibb, and others.
  • Promising Acute Myeloid Leukemia Pipeline Therapies in the various stages of development include Fosciclopirox + Cytarabine, CPX-351, Minnelide, SNDX-5613, ASTX727, KPT-9274, SAR445419, ADI-PEG 20, BP1002, CTX-712, BTX-A51, PRGN-3006 T Cells, LY3214996, Regorafenib, GDX012, MRX-2843, SC-DARIC33, CWP232291, TL-895, KRT-232, CYAD-02, MK-0482, and others.
  • April 2024: AbbVie announced a study of Phase 1 clinical trials for ABBV-787. A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-787 in Adult Subjects with Acute Myeloid Leukemia (AML).
  • April 2024: Kite, A Gilead Company announced a study of Phase 1 clinical trials for Cyclophosphamide, and Fludarabine. The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-222, in participants with relapsed/refractory (r/r) acute myeloid leukemia (AML).
  • April 2024: Astex Pharmaceuticals Inc. announced a study of Phase 1 & 2 clinical trials for Decitabine and Cedazuridine (ASTX727) and Venetoclax. The Phase 1 portion of this study is a single-arm, open-label, multicenter, non-randomized interventional study to evaluate the pharmacokinetic (PK) interaction, safety, and efficacy of ASTX727 when given in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. The primary purpose of the study is to rule out drug-drug interactions between ASTX727 and venetoclax combination therapy by evaluating area under the curve (AUC) and maximum plasma concentration (Cmax) exposure.

 

Discover which therapies are expected to grab the Acute Myeloid Leukemia Market Share @ Acute Myeloid Leukemia Market Outlook

 

Acute Myeloid Leukemia Overview

Acute myeloid leukemia (AML) (also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukaemia) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. AML can involve tissues outside the bone marrow and blood, including lymph nodes, the brain, skin, and other parts of the body.

 

Acute Myeloid Leukemia Epidemiology Insights

The epidemiology section of Acute Myeloid Leukemia offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

  • Total Acute Myeloid Leukemia Incident Cases
  • Acute Myeloid Leukemia Age-specific Cases
  • Acute Myeloid Leukemia Gender-specific Cases
  • Acute Myeloid Leukemia Mutation-specific Cases

 

Download the report to understand which factors are driving Acute Myeloid Leukemia Epidemiology trends @ Acute Myeloid Leukemia Epidemiological Insights

 

Acute Myeloid Leukemia Drugs Market

The Acute Myeloid Leukemia Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Acute Myeloid Leukemia signaling in Acute Myeloid Leukemia are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Acute Myeloid Leukemia Treatment Market Landscape

The Acute Myeloid Leukemia treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Acute Myeloid Leukemia has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To know more about Acute Myeloid Leukemia treatment guidelines, visit @ Acute Myeloid Leukemia Treatment Market Landscape

 

Acute Myeloid Leukemia Market Outlook

The report’s outlook on the Acute Myeloid Leukemia market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Acute Myeloid Leukemia therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Acute Myeloid Leukemia drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Acute Myeloid Leukemia market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Acute Myeloid Leukemia Drugs Uptake

The drug chapter of the Acute Myeloid Leukemia report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Acute Myeloid Leukemia.

 

Major Acute Myeloid Leukemia Companies

Several Acute Myeloid Leukemia Companies working in the market include Pfizer, Bristol Myers Squibb, Agios Pharmaceuticals, Abbvie, Jazz Pharmaceuticals, Astellas Pharma, Pfizer, Novartis Oncology, Daiichi Sankyo., Bristol Myers Squibb, AstraZeneca/Aex Pharmaceuticals, Inc., Chimerix, Takeda, Rafael Pharmaceuticals Inc., Delta-Fly Pharma, GlycoMimetics Incorporated, BerGenBio ASA, MacroGenics, Syndax Pharmaceuticals, Arog Pharmaceuticals, Forma Therapeutics, Sellas Life Sciences Group, Actinium Pharmaceuticals, Clear Creek Bio Inc., CellCentric Ltd., Biosight Ltd., Astex Pharmaceuticals, Inc., Curis, Inc., NexImmune Inc., Immunomedics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Incyte Corporation, Aprea Therapeutics, Immunicum/DCPrime BV, GT Biopharma Inc, Hanmi Pharmaceutical Company Limited, Cardiff Oncology, Bio-Path Holdings, Actinium Pharmaceuticals, Aptevo Therapeutics, Synimmune GmbH, GEMoaB Monoclonals, ImmunoGen Inc, AGC Biologics S.p.A., Precigen Inc, Novartis Pharmaceuticals, Xencor, Inc./Novartis, Celgene/Bristol Myers Squibb, and others.

 

Learn more about the FDA-approved drugs for Acute Myeloid Leukemia @ Drugs for Acute Myeloid Leukemia Treatment

 

Scope of the Acute Myeloid Leukemia Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Acute Myeloid Leukemia Companies- Pfizer, Bristol Myers Squibb, Agios Pharmaceuticals, Abbvie, Jazz Pharmaceuticals, Astellas Pharma, Pfizer, Novartis Oncology, Daiichi Sankyo., Bristol Myers Squibb, AstraZeneca/Aex Pharmaceuticals, Inc., Chimerix, Takeda, Rafael Pharmaceuticals Inc., Delta-Fly Pharma, GlycoMimetics Incorporated, BerGenBio ASA, MacroGenics, Syndax Pharmaceuticals, Arog Pharmaceuticals, Forma Therapeutics, Sellas Life Sciences Group, Actinium Pharmaceuticals, Clear Creek Bio Inc., CellCentric Ltd., Biosight Ltd., Astex Pharmaceuticals, Inc., Curis, Inc., NexImmune Inc., Immunomedics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Incyte Corporation, Aprea Therapeutics, Immunicum/DCPrime BV, GT Biopharma Inc, Hanmi Pharmaceutical Company Limited, Cardiff Oncology, Bio-Path Holdings, Actinium Pharmaceuticals, Aptevo Therapeutics, Synimmune GmbH, GEMoaB Monoclonals, ImmunoGen Inc, AGC Biologics S.p.A., Precigen Inc, Novartis Pharmaceuticals, Xencor, Inc./Novartis, Celgene/Bristol Myers Squibb, and others.
  • Acute Myeloid Leukemia Pipeline Therapies- Fosciclopirox + Cytarabine, CPX-351, Minnelide, SNDX-5613, ASTX727, KPT-9274, SAR445419, ADI-PEG 20, BP1002, CTX-712, BTX-A51, PRGN-3006 T Cells, LY3214996, Regorafenib, GDX012, MRX-2843, SC-DARIC33, CWP232291, TL-895, KRT-232, CYAD-02, MK-0482, and others.
  • Acute Myeloid Leukemia Market Dynamics: Acute Myeloid Leukemia Market Drivers and Barriers
  • Acute Myeloid Leukemia Market Access and Reimbursement, Unmet Needs, KOL’s Views, and Analyst’s Views

 

Discover more about Acute Myeloid Leukemia Drugs in development @ Acute Myeloid Leukemia Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Executive Summary of Acute Myeloid Leukemia (AML)

3. Competitive Intelligence Analysis for Acute Myeloid Leukemia (AML)

4. Acute Myeloid Leukemia (AML): Market Overview at a Glance

5. Acute Myeloid Leukemia (AML): Disease Background and Overview

6. Patient Journey

7. Acute Myeloid Leukemia (AML) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Acute Myeloid Leukemia (AML) Unmet Needs

10. Key Endpoints of Acute Myeloid Leukemia (AML) Treatment

11. Acute Myeloid Leukemia (AML) Marketed Products

12. Acute Myeloid Leukemia (AML) Emerging Therapies

13. Acute Myeloid Leukemia (AML): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Acute Myeloid Leukemia (AML)

17. KOL Views

18. Acute Myeloid Leukemia Market Drivers

19. Acute Myeloid Leukemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Myeloid Leukemia Market Size is Expected to Grow by 2032 | DelveInsight

Acute Liver Failure Market Size is Expected to Grow by 2032 | DelveInsight

DelveInsight’s “Acute Liver Failure Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Acute Liver Failure, historical and forecasted epidemiology as well as the Acute Liver Failure market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.

 

Key Takeaways from the Acute Liver Failure Market Research Report

  • The increase in Acute Liver Failure Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
  • As per DelveInsight analysis, the Acute Liver Failure market is anticipated to witness growth at a considerable CAGR.
  • The leading Acute Liver Failure Companies working in the market include Vital Therapies, AstraZeneca, Bristol-Myers Squibb, Beijing Continent Pharmaceutical Co, Ltd., GE Healthcare, Sinew Pharma Inc., Grifols Therapeutics LLC, Yaqrit Ltd, CytoSorbents Inc., Cellaion SA, and others.
  • Promising Acute Liver Failure Pipeline Therapies in the various stages of development include F573 for injection, Sterilizing water for injection, Ornithine Phenylacetate, 13C-Methacetin, and others.
  • April 2024: CytoSorbents Inc.,- Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care.
  • April 2024: Cellaion SA announced a study of Phase 2 clinical trials for HepaStem. This is an interventional, double blind, randomized (2:1), and placebo-controlled study of 2 infusions of a 1 dose regimen of HepaStem in patients recently diagnosed (≤1 week) with ACLF grade 1 or 2 on top of Standard of Care (SoC), and for whom the diagnosis is not resolved on the day of infusion.

 

Discover which therapies are expected to grab the Acute Liver Failure Market Share @ Acute Liver Failure Market Outlook

 

Acute Liver Failure Overview

 Acute Liver Failure is the development of sudden, severe hepatic dysfunction from an acute insult to the liver, associated with the onset of hepatic encephalopathy and coagulation abnormalities. American Association for the Study of Liver Diseases (AASLD) defines it as the evidence of coagulation abnormality, usually an international normalized ratio above 1.5, and any degree of mental alteration (encephalopathy) in a patient without preexisting liver disease and with an illness of fewer than 26 weeks’ duration.

 

Acute Liver Failure Epidemiology Insights

The epidemiology section of Acute Liver Failure offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

  • Total Acute Liver Failure Incident Cases
  • Acute Liver Failure Gender-specific Cases
  • Acute Liver Failure Age-specific Cases
  • Acute Liver Failure Etiology-specific Cases
  • Acute Liver Failure Treated Cases

 

Download the report to understand which factors are driving Acute Liver Failure Epidemiology trends @ Acute Liver Failure Epidemiological Insights

 

Acute Liver Failure Drugs Market

The Acute Liver Failure Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Acute Liver Failure signaling in Acute Liver Failure are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Acute Liver Failure Treatment Market Landscape

The Acute Liver Failure treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Acute Liver Failure has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To know more about Acute Liver Failure treatment guidelines, visit @ Acute Liver Failure Treatment Market Landscape

 

Acute Liver Failure Market Outlook

The report’s outlook on the Acute Liver Failure market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Acute Liver Failure therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Acute Liver Failure drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Acute Liver Failure market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Acute Liver Failure Drugs Uptake

The drug chapter of the Acute Liver Failure report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Acute Liver Failure.

 

Major Acute Liver Failure Companies

Several companies working in the market include Vital Therapies, AstraZeneca, Bristol-Myers Squibb, Beijing Continent Pharmaceutical Co, Ltd., GE Healthcare, Sinew Pharma Inc., Grifols Therapeutics LLC, Yaqrit Ltd, CytoSorbents Inc., Cellaion SA, and others.

 

Learn more about the FDA-approved drugs for Acute Liver Failure @ Drugs for Acute Liver Failure Treatment

 

Scope of the Acute Liver Failure Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Acute Liver Failure Companies- Vital Therapies, AstraZeneca, Bristol-Myers Squibb, Beijing Continent Pharmaceutical Co, Ltd., GE Healthcare, Sinew Pharma Inc., Grifols Therapeutics LLC, Yaqrit Ltd, CytoSorbents Inc., Cellaion SA, and others
  • Acute Liver Failure Pipeline Therapies- F573 for injection, Sterilizing water for injection, Ornithine Phenylacetate, 13C-Methacetin, and others.
  • Acute Liver Failure Market Dynamics: Acute Liver Failure Market Drivers and Barriers
  • Acute Liver Failure Market Access and Reimbursement, Unmet Needs, KOL’s Views, and Analyst’s Views

 

Discover more about Acute Liver Failure Drugs in development @ Acute Liver Failure Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Executive Summary

3. Competitive Intelligence Analysis

4. Acute Liver Failure: Market Overview at a Glance

5. Acute Liver Failure: Disease Background and Overview

6. Patient Journey

7. Acute Liver Failure Epidemiology and Patient Population

8. Acute Liver Failure Treatment Algorithm, Current Treatment, and Medical Practices

9. Acute Liver Failure Unmet Needs

10. Key Endpoints of Acute Liver Failure Treatment

11. Acute Liver Failure Marketed Products

12. Acute Liver Failure Emerging Therapies

13. Acute Liver Failure: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Acute Liver Failure Market Outlook

16. Access and Reimbursement Overview of Acute Liver Failure

17. KOL Views

18. Acute Liver Failure Market Drivers

19. Acute Liver Failure Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Liver Failure Market Size is Expected to Grow by 2032 | DelveInsight

Acute Kidney Injury Market Size in the 7MM was ~USD 6200 Million in 2022 | DelveInsight

DelveInsight’s “Acute Kidney Injury Market Insights, Epidemiology, and Market Forecast — 2034” report delivers an in-depth understanding of the Acute Kidney Injury, historical and forecasted epidemiology as well as the Acute Kidney Injury market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.

 

Key Takeaways from the Acute Kidney Injury Market Research Report

  • As per DelveInsight analysis, the Acute Kidney Injury market is anticipated to witness growth at a considerable CAGR.
  • The total Mortality-adjusted Incident Cases of Acute Kidney Injury in the 7MM comprised 14.6 million cases in 2022 and are projected to increase during the forecast period.
  • The total Mortality-adjusted Incident Cases of Acute Kidney Injury in the United States were approximately 5.7 in 2022.
  • The leading Acute Kidney Injury Companies working in the market include Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, and others.
  • Promising Acute Kidney Injury Pipeline Therapies in the various stages of development include TIN816, SCD-F40, THR-184, ABT-719, QPI-1002, ASP1128, LSALT Peptide, and others.
  • April 2024: AquaPass Medical Ltd- This study requires several investigational tests, exams, and data collection procedures to be performed by the participants. These procedures are listed in abbreviated format in the Schedule of Assessments/Activities table. The final eligibility of the trial will be confirmed after a 2-hour acclimatization session.
  • April 2024: Novartis Pharmaceuticals announced a study of Phase 2 clinical trials for TIN816 70 mg lyophilisate powder. The purpose of this study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile and to evaluate the safety and tolerability of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis-associated acute kidney injury (SA-AKI).
  • April 2024: Arch Biopartners Inc. announced a study of Phase 2 clinical trials for LSALT Peptide. This study is a randomized, double-blind, multicenter interventional study to assess safety and efficacy of LSALT peptide versus placebo (matching drug-free saline) in patients undergoing on-pump cardiac surgery. Patients will be followed for safety and efficacy up to Day 28 (EOS), with Day 1 being the day of randomization of study drug administered at least 1 hour prior to induction of anesthesia.

 

Discover which therapies are expected to grab the Acute Kidney Injury Market Share @ Acute Kidney Injury Market Outlook

 

Acute Kidney Injury Overview

Acute Kidney Injury is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over hours to weeks. Signs and symptoms of Acute Kidney Injury include nausea, vomiting, weakness, dizziness, and, pain in the lower back. Some patients are asymptomatic (no noticeable symptoms) and others may have generalized non-specific (not specific to kidneys) symptoms.

 

Acute Kidney Injury Epidemiology Insights

The epidemiology section of Acute Kidney Injury offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

  • Total Acute Kidney Injury Incident Population in Hospitalized Patients
  • Acute Kidney Injury Mortality Adjusted Incident Population
  • Acute Kidney Injury Stage-specific Incident Population
  • Acute Kidney Injury Age-specific Incident Population

 

Download the report to understand which factors are driving Acute Kidney Injury Epidemiology trends @ Acute Kidney Injury Epidemiological Insights

 

Acute Kidney Injury Drugs Market

The Acute Kidney Injury Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Acute Kidney Injury signaling in Acute Kidney Injury are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Acute Kidney Injury Treatment Market Landscape

The Acute Kidney Injury treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Acute Kidney Injury has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To know more about Acute Kidney Injury treatment guidelines, visit @ Acute Kidney Injury Treatment Market Landscape

 

Acute Kidney Injury Market Outlook

The report’s outlook on the Acute Kidney Injury market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Acute Kidney Injury therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Acute Kidney Injury drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Acute Kidney Injury market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Acute Kidney Injury Drugs Uptake

The drug chapter of the Acute Kidney Injury report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Acute Kidney Injury.

 

Major Acute Kidney Injury Companies

Several Acute Kidney Injury Companies working in the market include Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, and others.

 

Learn more about the FDA-approved drugs for Acute Kidney Injury @ Drugs for Acute Kidney Injury Treatment

 

Scope of the Acute Kidney Injury Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Acute Kidney Injury Companies- Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, and others.
  • Acute Kidney Injury Pipeline Therapies- TIN816, SCD-F40, THR-184, ABT-719, QPI-1002, ASP1128, LSALT Peptide, and others.
  • Acute Kidney Injury Market Dynamics: Acute Kidney Injury Market Drivers and Barriers
  • Acute Kidney Injury Market Access and Reimbursement, Unmet Needs, KOL’s Views, and Analyst’s Views

 

Discover more about Acute Kidney Injury Drugs in development @ Acute Kidney Injury Clinical Trials Assessment

 

Table of Content

1. KEY INSIGHTS

2. REPORT INTRODUCTION

3. EXECUTIVE SUMMARY

4. KEY EVENTS

5. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY

6. ACUTE KIDNEY INJURY MARKET OVERVIEW AT A GLANCE

7. DISEASE BACKGROUND AND OVERVIEW

8. TREATMENT AND PREVENTION

9. GUIDELINES

10. EPIDEMIOLOGY AND PATIENT POPULATION

11. PATIENT JOURNEY

12. EMERGING DRUGS

13. Acute Kidney Injury: THE 7MM ANALYSIS

14. KOL VIEWS

15. UNMET NEEDS

16. SWOT ANALYSIS

17. MARKET ACCESS AND REIMBURSEMENT

18. APPENDIX

19. DELVEINSIGHT CAPABILITIES

20. DISCLAIMER

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Kidney Injury Market Size in the 7MM was ~USD 6200 Million in 2022 | DelveInsight